According to the company`s press release, Kayentis, a global provider of digital data capture systems for clinical trials, has raised $8.3 million in growth capital. The round was led by its historical investors Extens and LBO France with participation from Bpifrance.
Founded in 2003 by Philippe Berna, Kayentis is a global provider of digital data capture technologies for sponsors, sites, and patients in clinical trials, focuses on bringing simplicity, efficiency, and integrity to the collection of clinical trial data. Kayentis within the last ten years has specialized in electronic Clinical Outcome Assessment (eCOA) solutions for phase II/III research in a broad range of therapeutic areas.
The new funding will take Kayentis beyond eCOA with more options designed to enhance the patient experience and support clinical trial digitalization. To date, Kayentis has conducted digital data collection for over 220 clinical trials in 79 countries, employing 120 different languages. Headquartered in France, Kayentis also has operations in Boston and in Tokyo.
“This new funding is testimony to the trust our shareholders hold in Kayentis’ potential. It shows their confidence in our abilities to fully satisfy the demands for digital data integrity and expertise in the growing clinical trials market,” said Guillaume Juge, CEO of Kayentis. “Our roadmap is geared towards providing more innovation and operational capacity to support the trend towards virtual, decentralized and remote trials, where patient-facing digital technologies are increasingly playing an important role; these provisions are pivotal in helping our clients bring important therapies to market.”
